StreetInsider.com News Articles

Palisade Bio to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 09:00:00 -0400

Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026.

Wells Fargo 2026 Healthcare Conference

Dates: September 8–10, 2026
Location: Boston, Massachusetts
Format: Investor meetings

Morgan Stanley 24th Annual Global Healthcare Conference

Dates: September 14–16, 2026
Location: New York, New York
Fireside Chat: Wednesday, September 16, 2026, from 10:00–10:35

Palisade Bio to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 09:00:00 -0400

Wells Fargo 2026 Healthcare Conference

Dates: September 8–10, 2026
Location: Boston, Massachusetts
Format: Investor meetings

Morgan Stanley 24th Annual Global Healthcare Conference

Dates: September 14–16, 2026
Location: New York, New York
Fireside Chat: Wednesday, September 16, 2026, from 10:00–10:35

Form 4 PALISADE BIO, INC. For: Aug 19 Filed by: Finley John David

Fri, 21 Aug 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962668.html

Form 4 PALISADE BIO, INC. For: Aug 19 Filed by: Finley John David

Fri, 21 Aug 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962668.html

Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932091.html

Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932091.html

Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917410.html

Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917410.html

Palisade Bio Inc. (PALI) Reports In-Line Q2 EPS

Mon, 10 Aug 2026 16:56:07 -0400

Palisade Bio Inc. (NASDAQ: PALI) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $500 thousand.

For earnings history and earnings-related data on Palisade Bio Inc. (PALI) click here.

Palisade Bio posts wider Q2 loss as PALI-2108 Phase 2 trial nears

Mon, 10 Aug 2026 16:20:22 -0400

Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, reported a net loss of $10.6 million, or $0.05 per share, for the second quarter ended June 30, 2026, compared to a net loss of $2.8 million, or $0.58 per share, for the same period in 2025, according to a company press release.

Research and development expenses rose to $7.4 million from $1.7 million a year earlier, driven by higher employee-related costs, increased clinical operations, and chemistry, manufacturing and controls activities tied to PALI-2108. General and administrative expenses increased to $4.8 million from $1.2 million. The company recorded $0.5 million in license

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Mon, 10 Aug 2026 16:20:00 -0400

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD)

Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027

IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026

Strong balance sheet expected to support execution through key Phase 2 clinical readouts

Denver, CO, Aug. 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Mon, 10 Aug 2026 16:20:00 -0400

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD)

Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027

IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026

Strong balance sheet expected to support execution through key Phase 2 clinical readouts

Denver, CO, Aug. 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Mon, 10 Aug 2026 16:20:00 -0400

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD)

Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027

IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026

Strong balance sheet expected to support execution through key Phase 2 clinical readouts

Denver, CO, Aug. 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Mon, 10 Aug 2026 16:20:00 -0400

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD)

Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027

IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026

Strong balance sheet expected to support execution through key Phase 2 clinical readouts

Denver, CO, Aug. 10, 2026

Form 8-K PALISADE BIO, INC. For: Aug 10

Mon, 10 Aug 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260810/26898218.html

Form 8-K PALISADE BIO, INC. For: Aug 10

Mon, 10 Aug 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260810/26898218.html

Form 10-Q PALISADE BIO, INC. For: Jun 30

Mon, 10 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260810/26897864.html

Form 10-Q PALISADE BIO, INC. For: Jun 30

Mon, 10 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260810/26897864.html

Form SCHEDULE 13G PALISADE BIO, INC. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400
si-local-file:///var/storage/secattach/20260729/26834393.html

Form SCHEDULE 13G PALISADE BIO, INC. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400
si-local-file:///var/storage/secattach/20260729/26834393.html

Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform

Thu, 23 Jul 2026 06:06:50 -0400
(Updated - July 23, 2026 6:06 AM EDT)
Oppenheimer analyst Leland Gershell initiated Palisade Bio Inc. (NASDAQ: PALI) at Outperform with a price target of $8.00.
The analyst commented: "We believe PALI offers investors an attractive way to participate in the large/growing inflammatory bowel disease (IBD) space as the company's therapeutic development programs—whose approach is orthogonal to those of ABVX and EQ and backed by compelling early clinical results—move toward their first Phase 2 readout next year. We believe PALI‑2108’s appeal lies in its potential for biologic-like early symptom improvement paired with a once-daily oral profile better suited for long-term maintenance—a profile

Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform

Thu, 23 Jul 2026 06:06:50 -0400
(Updated - July 23, 2026 6:06 AM EDT)
Oppenheimer analyst Leland Gershell initiated Palisade Bio Inc. (NASDAQ: PALI) at Outperform with a price target of $8.00.
The analyst commented: "We believe PALI offers investors an attractive way to participate in the large/growing inflammatory bowel disease (IBD) space as the company's therapeutic development programs—whose approach is orthogonal to those of ABVX and EQ and backed by compelling early clinical results—move toward their first Phase 2 readout next year. We believe PALI‑2108’s appeal lies in its potential for biologic-like early symptom improvement paired with a once-daily oral profile better suited for long-term maintenance—a profile

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400
si-local-file:///var/storage/secattach/20260710/26758186.html

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400
si-local-file:///var/storage/secattach/20260710/26758186.html

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts.

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,